Fresenius Medical Care AG

FMS · XETRA

$22.68+$0.45 (+2.02%)TodayMarket closed ·
Prev close $22.23

Latest news

  • Press releasePRNewswire

    Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™

  • Press releasePRNewswire

    Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026

  • Press releasePRNewswire

    Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth

  • News

    Fresenius Medical Care Shares Halted, News Pending

  • NewsVandana Singh

    Fresenius Medical Care Refines China Strategy With Targeted Product Focus

  • Press releasePRNewswire

    Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership

  • NewsVandana Singh

    FDA Slams Fresenius Over Leaking Dialysis Bags, Warns of Potentially Life-Threatening Risk

  • Press releasePRNewswire

    Fresenius Medical Care Announces Publication of a Multinational Real-World Evidence Study Associating High-Volume Hemodiafiltration with Lower Mortality Risk Than Conventional Hemodialysis

  • News

    Fresenius Medical Care Q2 2026 Earnings Call Transcript

  • NewsAvi Kapoor

    Powell Industries Posts Downbeat Q3 Results, Joins Clearpoint Neuro, Ichor Holdings And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

  • News

    Fresenius Medical Care Q2 Adj. EPS $0.66 Beats $0.64 Estimate, Sales $5.651B Miss $5.720B Estimate

  • Press releasePRNewswire

    Fresenius Medical Care appoints Cassie McLean as new Management Board Member for Care Delivery

  • Press releasePRNewswire

    Fresenius Medical Care accelerates income growth to 23% in the second quarter of 2026 while advancing its strategic agenda

  • Press releasePRNewswire

    Fresenius Medical Care announces BEACON-US, generating real-world evidence supporting high-volume hemodiafiltration for U.S. dialysis patients

  • Press releasePRNewswire

    Fresenius Medical Care introduces TherapyWise™ analytics for kidney replacement therapy

  • Press releasePRNewswire

    Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysis

  • Press releasePRNewswire

    Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million

  • Press releasePRNewswire

    Fresenius Medical Care highlights new renal research and innovation at ERA Congress 2026

  • Press releasePRNewswire

    Fresenius Medical Care announces new share buyback program with a total volume of around EUR 1 billion with phased execution over 12 months

  • Press releasePRNewswire

    Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care

  • Press releasePRNewswire

    Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer

  • News

    Earnings Scheduled For May 5, 2026

  • Press releasePRNewswire

    Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed

  • News

    Fresenius Medical Care Q1 Adj. EPS $0.53 Misses $0.59 Estimate, Sales $5.401B Miss $5.720B Estimate

  • NewsAvi Kapoor

    Ultra Clean Posts Downbeat Earnings, Joins Paymentus, Whirlpool And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

  • Press releasePRNewswire

    Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

  • News

    Fresenius Medical Care: Q4 Earnings Insights

  • Press releasePRNewswire

    Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned

  • Press releasePRNewswire

    Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board

  • Press releasePRNewswire

    Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025

  • Press releasePRNewswire

    Fresenius Medical Care highlights real-world advances in hemodiafiltration and AI at ASN Kidney Week 2025

  • Press releasePRNewswire

    Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement

  • Press releasePRNewswire

    Fresenius Medical Care advances its FME Reignite strategy by increasing ownership in its Value-Based Care asset and appointing a new leader for the operating segment

  • NewsAvi Kapoor

    Canopy Growth, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

  • NewsVandana Singh

    Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum

  • Press releasePRNewswire

    Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework

  • NewsEuropean Capital Insights

    Dollar's Worst Start Since 1970s Could Dent European Corporate Profits

  • Press releasePRNewswire

    Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025

  • News

    Fresenius Launches 'FME Reignite' With $1B Annual Capex Plan and $1.05B Cost Savings Target by 2027

  • Press releasePRNewswire

    Fresenius Medical Care Launches its Strategy FME Reignite with increased Profitability Aspirations, and a New Capital Allocation Framework to further enhance Value Creation

  • Press releasePRNewswire

    Fresenius Medical Care starts 2025 with strong organic revenue and income growth

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.